Corporate

QPS Announces Paul A. Lehman as New Vice President of Dermal and Transdermal Research Services - June, 2013

Newark, DE; June 26, 2013 - QPS Holdings, LLC, a leading full-service contract research organization, has named Paul A. Lehman, MSc as Vice President and Head of Dermal and Transdermal Research. Mr. Lehman will work with QPS’ Strategic Leadership Team and Clinical Research Management to assist clients in quickly moving their formulations from pre-clinical through late stage development.

“With QPS’ increasing global presence in early clinical research, it is my pleasure to announce the hiring of Paul Lehman,” said Ben Chien, PhD, QPS President and CEO. “In his new position, Paul will direct our new Dermal and Transdermal contract research service division by establishing study designs and study conduct processes while serving as the resident scientific expert for our clients. Paul will be a major asset in this exciting and extremely important role, so crucial for the future success of our clients.”

Paul Lehman is well known throughout the clinical research industry, with over 33 years of experience in topical and transdermal pharmacokinetics and their bioequivalence. He has been a Principal Investigator, Sub-Investigator, Principal Scientist or Study Director for more than 600 clinical and in vitro preclinical studies for the pharmaceutical, toxicology, skin care, and veterinary industries. His bibliography currently includes 44 published manuscripts, 5 book chapters, and over 125 poster and lecture presentations.

Mr. Lehman has been an integral partner with Dr. Thomas Franz (innovator of the Franz Diffusion Cell) since 1980, conducting in vitro and in vivo topical pharmacokinetics studies and developing and validating bioequivalence models for topical formulations. The Franz Diffusion Cell has become the industry standard model for determining in vitro percutaneous absorption kinetics of topical and transdermal products using ex vivo human skin. This model and associated methodologies support drug development in the preclinical, clinical, and post-approval phases, including the in vitro rate-of-release assay (IVRT) based on the FDA SUPAC-SS Guidance.

Mr. Lehman is also well known throughout the industry for his experience with global regulatory requirements, including those of the EMA, FDA, and OECD; for assisting in study and product development design; and for directing the conduct of clinical research on topical and transdermal products. His experience in human dermal safety, topical pharmacokinetics, bioavailability and bioequivalence, cumulative irritation, sensitization, adhesion, and vasoconstriction for topical corticosteroid bioequivalence, as well as marketing claim substantiation and the design of studies for unique products, including devices, has earned him recognition as an expert in these fields.

About QPS

QPS is a GLP/GCP-compliant CRO that supports discovery and preclinical and clinical drug development. We provide quality services in Neuropharmacology, Drug Metabolism and Pharmacokinetics, Toxicology, Bioanalysis, Translational Medicine, and Early & Late Phase Clinical Research to clients worldwide. Our 30+ regional laboratories, clinical facilities and offices are located in North America, Europe and Asia. For more information, visit http://www.qps.com

Contact

Reinier Schwietert 
Vice President of Global Marketing
QPS Holdings, LLC
Delaware Technology Park
3 Innovation Way, Suite 240
Newark, DE 19711
USA
 +31 (50) 304 8003
Reinier.Schwietert@qps.com
www.qps.com

QPS is a GLP/GCP-compliant CRO that supports discovery and preclinical and clinical drug development. We provide quality services in Neuropharmacology, Drug Metabolism and Pharmacokinetics, Toxicology, Bioanalysis, Translational Medicine, and Early & Late Phase Clinical Research to clients worldwide. Our 30+ regional laboratories, clinical facilities and offices are located in North America, Europe and Asia. For more information, visit http://www.qps.com

Contact

Reinier Schwietert 
Vice President of Global Marketing
QPS Holdings, LLC
Delaware Technology Park
3 Innovation Way, Suite 240
Newark, DE 19711
USA
 

+31 (50) 304 8003
Reinier.Schwietert@qps.com
www.qps.com

back
top
20 years in pharma R&D navigation